Fusion Antibodies (LON:FAB) Trading Up 3.4% – Here’s What Happened

Fusion Antibodies plc (LON:FAB)’s stock price shot up 3.4% on Tuesday . The company traded as high as GBX 15 and last traded at GBX 15. 383,697 shares were traded during mid-day trading, a decline of 27% from the average session volume of 525,127 shares. The stock had previously closed at GBX 14.50.

Fusion Antibodies Stock Up 3.4%

The firm has a market cap of £17.05 million, a price-to-earnings ratio of -10.00 and a beta of 0.49. The stock’s 50 day moving average is GBX 14.43 and its 200 day moving average is GBX 14.27. The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40.

Fusion Antibodies (LON:FAB) last released its earnings results on Monday, November 24th. The company reported GBX (0.50) earnings per share for the quarter. Fusion Antibodies had a negative return on equity of 137.11% and a negative net margin of 195.95%. Analysts forecast that Fusion Antibodies plc will post -129.9999875 EPS for the current year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.